Condition: Uterine Cancer · Endometrial Cancer · Sponsor: Washington University School of Medicine
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
This description comes directly from the study's public registry record.
David G Mutch, M.D. · 314-362-3181 · mutchd@wustl.edu
Always discuss trial participation with your own doctor first.
| University of California, San Francisco | San Francisco, California, United States | Not Yet Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| University of New Mexico | Albuquerque, New Mexico, United States | Not Yet Recruiting |
| University of Oklahoma | Oklahoma City, Oklahoma, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06795009